Luedtke R R, Korner M, Neve K A, Molinoff P B
Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia 19104-6084.
J Neurochem. 1988 Apr;50(4):1253-62. doi: 10.1111/j.1471-4159.1988.tb10602.x.
A diverse panel of monoclonal antibodies was obtained from BALB/c mice immunized with two haptens structurally related to spiroperidol (SPD). Bromoacetyl derivatives of aminospiroperidol (NH2SPD) and N-amino-phenethylspiroperidol (NAPS) were synthesized to couple the haptens covalently to a protein carrier for immunization, thereby maintaining the butyrophenone portion of the immunogen. Hybridomas were selected based on their ability to secrete antibody that binds [3H]SPD with high affinity. Equilibrium dissociation constants for these antibodies ranged from 0.2 to greater than 100 nM. The antigen binding sites of the anti-NH2SPD and anti-NAPS antibodies were characterized in studies of the inhibition of the binding of [3H]-SPD by a series of ligands that are either (a) structurally related to SPD or (b) structurally unrelated to the butyrophenones but known to be selective antagonists of the D2 subtype of dopamine receptor. Based on the patterns of inhibition of the binding of [3H]SPD by these compounds, 12 classes of antibody combining sites were identified. Most of these antibodies bound butyrophenones with high affinity. One anti-NH2SPD and four anti-NAPS antibodies also bound domperidone, a nonbutyrophenone that has a high affinity for D2 receptors. None of the antibodies bound clebopride or sulpiride, D2-selective antagonists of the benzamide class, or the agonist dopamine.
用两种与螺哌啶醇(SPD)结构相关的半抗原免疫BALB/c小鼠,获得了一组多样的单克隆抗体。合成了氨基螺哌啶醇(NH2SPD)和N-氨基苯乙基螺哌啶醇(NAPS)的溴乙酰衍生物,将半抗原共价偶联到蛋白质载体上用于免疫,从而保留免疫原的丁酰苯部分。根据杂交瘤分泌能与[3H]SPD高亲和力结合的抗体的能力进行筛选。这些抗体的平衡解离常数范围为0.2至大于100 nM。在一系列配体对[3H]-SPD结合的抑制研究中,对抗NH2SPD和抗NAPS抗体的抗原结合位点进行了表征,这些配体要么(a)与SPD结构相关,要么(b)与丁酰苯结构无关,但已知是多巴胺受体D2亚型的选择性拮抗剂。根据这些化合物对[3H]SPD结合的抑制模式,鉴定出12类抗体结合位点。这些抗体中的大多数与丁酰苯具有高亲和力。一种抗NH2SPD抗体和四种抗NAPS抗体也与多潘立酮结合,多潘立酮是一种对D2受体具有高亲和力的非丁酰苯。没有一种抗体与氯波必利或舒必利(苯甲酰胺类的D2选择性拮抗剂)或激动剂多巴胺结合。